February 2021

Abstract

ASCO GU Symposium

Real-world treatment patterns and sequencing for metastatic renal cell carcinoma: results from the Flatiron database

George, S, Faccone, J, Huo, S, Zhang, Y, Stwalley, B, Hamilton, M, Le, TK, Ejzykowicz, F

February 2021

Abstract

ASCO GU Symposium

November 2020

Abstract

EU ISPOR

Flatiron-authored

Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies

Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R

May 2020

Abstract

ASCO Annual Meeting

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

December 2018

Abstract

Machine Learning for Health (ML4H) Workshop

Flatiron-authored

Disparities in the use of programmed death 1 immune checkpoint inhibitors

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks

Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP

March 2017

Abstract

ASCO Quality Care Symposium

Flatiron-authored